The Efficacy and Safety of Lenvatinib Combined With Sindilimab and Nab-paclitaxel in the First-line Treatment for Recurrent and Metastatic Triple Negative Breast Cancer: a Phase Ib/IIa Clinical Trial.
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Sindilimab|DRUG: Nab-paclitaxel|DRUG: Lenvatinib
Sponsor: Zhejiang Cancer Hospital